PCN213 COST-UTILITY ANALYSIS OF ABIRATERONE IN THE TREATMENT OF DOCETAXEL-REFRACTORY METASTATIC CASTRATION-RESISTANT PROSTATE CANCER COMPARED TO BEST SUPPORTIVE CARE IN IRAN

Value in Health ◽

10.1016/j.jval.2019.09.409 ◽

2019 ◽

Vol 22 ◽

pp. S477

Author(s):

S. Taheri ◽

Z. Karimi Majd ◽

N. Yousefi ◽

F. Peiravian

Keyword(s):

Prostate Cancer ◽

Supportive Care ◽

Best Supportive Care ◽

Cost Utility ◽

Cost Utility Analysis ◽

Castration Resistant Prostate Cancer ◽

Utility Analysis ◽

Castration Resistant

Download Full-text

Cost-Utility Analysis Of Enzalutamide For Patients With Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer (Mcrpc) After Failure Of Androgen Deprivation Therapy (Adt)

Value in Health ◽

10.1016/j.jval.2015.09.1266 ◽

2015 ◽

Vol 18 (7) ◽

pp. A474

Author(s):

C Vicente ◽

A Loblaw ◽

S North ◽

W Kassouf ◽

S Naidoo ◽

...

Keyword(s):

Prostate Cancer ◽

Androgen Deprivation Therapy ◽

Cost Utility ◽

Cost Utility Analysis ◽

Androgen Deprivation ◽

Castration Resistant Prostate Cancer ◽

Utility Analysis ◽

Castration Resistant

Download Full-text

Cost-Utility Analysis of Enzalutamide for Patients with Previously Treated Metastatic Castration-Resistant Prostate Cancer (MCRPC)

Value in Health ◽

10.1016/j.jval.2014.03.521 ◽

2014 ◽

Vol 17 (3) ◽

pp. A89-A90 ◽

Author(s):

C. Vicente ◽

V. Babashov ◽

F. Husein ◽

F. Saad ◽

S. Naidoo ◽

...

Keyword(s):

Prostate Cancer ◽

Cost Utility ◽

Cost Utility Analysis ◽

Castration Resistant Prostate Cancer ◽

Utility Analysis ◽

Castration Resistant ◽

Previously Treated

Download Full-text

PDG88 COST-UTILITY ANALYSIS OF ABIRATERONE VERSUS ENZALUTAMIDE IN THE TREATMENT OF METASTATIC CASTRATION-RESISTANT PROSTATE CANCER AFTER FAILURE OF ANDROGEN DEPRIVATION THERAPY

Value in Health ◽

10.1016/j.jval.2019.09.1101 ◽

2019 ◽

Vol 22 ◽

pp. S611-S612

Author(s):

L. Silva Miguel ◽

A.T. Paquete ◽

M. Borges

Keyword(s):

Prostate Cancer ◽

Androgen Deprivation Therapy ◽

Cost Utility ◽

Cost Utility Analysis ◽

Androgen Deprivation ◽

Castration Resistant Prostate Cancer ◽

Utility Analysis ◽

Castration Resistant

Download Full-text

Results and implications of using a new eq-5d value set for cost-utility analyses in sweden. An application using enzalutamide (xtandi®) verse best supportive care for treatment of metastatic castration resistant prostate cancer (MCRPC)

Value in Health ◽

10.1016/j.jval.2014.08.2350 ◽

2014 ◽

Vol 17 (7) ◽

pp. A648 ◽

Author(s):

O. Ghatnekar ◽

K. Nørgaard ◽

K. Skaltsa

Keyword(s):

Prostate Cancer ◽

Supportive Care ◽

Best Supportive Care ◽

Cost Utility ◽

Castration Resistant Prostate Cancer ◽

Value Set ◽

Castration Resistant

Download Full-text

A cost-utility analysis of SIR-Spheres Y-90 resin microspheres versus best supportive care in the treatment of unresectable metastatic colorectal cancer refractory to chemotherapy in the UK

Journal of Medical Economics ◽

10.1080/13696998.2020.1839273 ◽

2020 ◽

pp. 1-10

Author(s):

V. K. Brennan ◽

F. Colaone ◽

S. Shergill ◽

R. F. Pollock

Keyword(s):

Colorectal Cancer ◽

Supportive Care ◽

Metastatic Colorectal Cancer ◽

Best Supportive Care ◽

Cost Utility ◽

Cost Utility Analysis ◽

Utility Analysis ◽

Resin Microspheres ◽

The Uk ◽

Unresectable Metastatic Colorectal Cancer

Download Full-text

Multicenter, Randomized, Double-Blind Phase Ii Study of Sorafenib Compared to Placebo with Best Supportive Care After Failure of Docetaxel in Metastatic Castration-Resistant Prostate Cancer

Annals of Oncology ◽

10.1093/annonc/mdu336.21 ◽

2014 ◽

Vol 25 ◽

pp. iv266

Author(s):

G. Kramer ◽

A. Maj-Hes ◽

A. Hobisch ◽

S.F. Shariat ◽

W. Loidl

Keyword(s):

Prostate Cancer ◽

Supportive Care ◽

Phase Ii ◽

Phase Ii Study ◽

Best Supportive Care ◽

Castration Resistant Prostate Cancer ◽

Double Blind ◽

Castration Resistant

Download Full-text

Cost-Utility Analysis (cua) Of First-Line Disease-Modifying Treatments (DMT) Versus Best Supportive Care (Bsc) In Finnish Relapsing-Remitting Multiple Sclerosis (RRMS) Patients

Value in Health ◽

10.1016/j.jval.2014.08.906 ◽

2014 ◽

Vol 17 (7) ◽

pp. A399 ◽

Author(s):

E. Soini ◽

C. Asseburg ◽

M.L. Sumelahti

Keyword(s):

Multiple Sclerosis ◽

Supportive Care ◽

Best Supportive Care ◽

Cost Utility ◽

Cost Utility Analysis ◽

Utility Analysis ◽

Relapsing Remitting ◽

Disease Modifying ◽

Relapsing Remitting Multiple Sclerosis

Download Full-text

701 Cost-utility analysis of onabotulinumtoxinA versus best supportive care in the treatment of idiopathic overactive bladder with urinary incontinence among patients not adequately managed with anticholinergic therapy

European Urology Supplements ◽

10.1016/s1569-9056(14)60691-6 ◽

2014 ◽

Vol 13 (1) ◽

pp. e701 ◽

Author(s):

N. Freemantle ◽

K. Khalaf ◽

C. Loveman ◽

S. Stanisic ◽

D. Gultyaev ◽

...

Keyword(s):

Urinary Incontinence ◽

Overactive Bladder ◽

Supportive Care ◽

Best Supportive Care ◽

Cost Utility ◽

Cost Utility Analysis ◽

Utility Analysis ◽

Anticholinergic Therapy

Download Full-text

PCN51 SIR-Spheres Y-90 Resin Microspheres Versus Best Supportive Care in the Treatment of Unresectable Metastatic Colorectal Cancer Refractory to Chemotherapy: A Cost-Utility Analysis in the UK

Value in Health ◽

10.1016/j.jval.2020.08.188 ◽

2020 ◽

Vol 23 ◽

pp. S430

Author(s):

V.K. Brennan ◽

F. Colaone ◽

S. Shergill ◽

R.F. Pollock

Keyword(s):

Colorectal Cancer ◽

Supportive Care ◽

Metastatic Colorectal Cancer ◽

Best Supportive Care ◽

Cost Utility ◽

Cost Utility Analysis ◽

Utility Analysis ◽

Resin Microspheres ◽

The Uk ◽

Unresectable Metastatic Colorectal Cancer

Download Full-text

CO1 A COST-UTILITY ANALYSIS OF DEGARELIX IN THE TREATMENT OF PROSTATE CANCER IN CHINA

Value in Health ◽

10.1016/j.jval.2019.04.019 ◽

2019 ◽

Vol 22 ◽

pp. S35-S36

Author(s):

F. Yang ◽

X. Du ◽

J. Xuan ◽

J. Fei

Keyword(s):

Prostate Cancer ◽

Cost Utility ◽

Cost Utility Analysis ◽

Utility Analysis

Download Full-text